Latest Breaking News On - Daiichi sankyo europe gmb - Page 14 : comparemela.com

Daiichi Sankyo: European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk

Daiichi Sankyo: European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomKausik rayWolfgang schiesslDaiichi sankyoGarth virginDaiichi sankyo europeDaiichi sankyo europe gmbProfessor of public healthAmerican college of cardiologyPortfolio communicationsSustainable development of societyEuropean society of cardiologyJournal of the american college cardiologyInnovative global healthcare companyEuropean medicines agency

Daiichi Sankyo: New data support the use of LIXIANA (edoxaban) in complex patient populations with atrial fibrillation (AF)

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in clinical routine practice in subpopulations including frail patients and those with worsening renal function. ENVISAGE-TAVI

George dangasWolfgang schiesslHein heidbuchelNicolas van mieghemDaiichi sankyoDaiichi sankyo europeDaiichi sankyo europe gmbEuropean heart rhythm associationMichaela wiener cardiovascular instituteCardiology at antwerp universityInternational society on thrombosisErasmus university medical centerPortfolio communicationsSustainable development of societyEuropean association for cardioIcahn school of medicine at mount sinai

Daiichi Sankyo Company, Limited: DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU Initiated in Patients with HER2 Positive Advanced Gastric Cancer

Daiichi Sankyo Company, Limited: DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU Initiated in Patients with HER2 Positive Advanced Gastric Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMasashi kawaseDaiichi sankyoDaiichi sankyo europe gmbDon murphyPlexxikon incDaiichi sankyo companyOncology developmentDaiichi sankyo incClinical development programSustainable development of societyDaiichi sankyo co ltdInnovative global healthcare companyCancer research united kingdomInternational agency of cancer research

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Regina gasslerMichael toiflKristin tessadriDaiichi sankyo europe gmbLiane fendtFlorian kronenbergGabriele baurMartina schulzMonika baylacherNihad muricCompetence centerGermany federal institute for drugsUniversity hospital munichBoehringer ingelheimAustria austrian agency for healthAustrian science fund

Daiichi Sankyo Company, Limited: Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma

Oral presentation highlights data from phase 1 study of valemetostat showing promising clinical activity in patients with relapsed/refractory PTCL and ATL Pivotal phase 2 study VALENTINE-PTCL01

United statesMasashi kawaseKen takeshitaDaiichi sankyoShigeru kusumotoDaiichi sankyo europe gmbJennifer brennanPlexxikon incDaiichi sankyo companyDaiichi sankyo incEuropean hematology associationLymphoma societySustainable development of societyDaiichi sankyo co ltdGlobal head of researchJapan ministry of health